4,901 trials
Hypertension, Pulmonary
Primary: Volume of Distribution of Radiolabeled GSK2256098 Measured by PET Scan — 1.0811; 1.3027; 0.8117; 0.5571 Milliliter per cubic centimeter(mL/cm^3)
Postural Orthostatic Tachycardia Syndrome (POTS)
Primary: Mean Arterial Blood Pressure Change — 14; 10 mmHg
Healthy
Primary: Cmax for Linagliptin — 15.1; 8.43 nmol/L
Healthy Volunteers
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219 Fasted vs. High-Fat Arms — 111; 137 nanogram/milliliter (ng/mL)
Acute Coronary Syndrome
Primary: Adverse Events of LC23-1306
MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 2; 6; 8 Participants
Respiratory Syncytial Virus (RSV)
Primary: Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers — 864; 914; 843; 234 Titers
Metastatic Cancer
Primary: Number of Participants With Clinically Significant Adverse Events (AEs) (Physical Assessments and Clinical Lab Tests) — 2; 4; 4; 8 Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin — 12100; 16800 Nanogram*Hour per Milliliter…
Healthy Volunteers
Primary: Urinary and Fecal Excretion of LY2835219-Related Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 3.43; 81.0 percentage…
Leukaemia, Myelocytic, Acute
Primary: Number of Patients With Severe Toxicities — 1; 1; 1; 1 Participants
Locally Advanced or Metastatic Solid Tumors
Primary: Number of Participants With a Dose-limiting Toxicity (DLT) — 0; 2; 2; 1 Participants
Diabetes Mellitus, Type 1
Primary: Blood Glucose Measures in Subjects Treated With Sitagliptin, Compared to the Placebo — 149.7; 155.9 mg/dl
Carcinoma, Non-Small-Cell Lung
Primary: Number of Patients Experiencing Dose Limiting Toxicity (DLT) in Cycle 1 — 2; 0; 2; 1 Participants
Advanced Cancer
Primary: Recommended Dose and Schedule for Phase 2 Studies — 8 mg/m^2/day